RealSelf recorded a 2,080% spike in GLP-1-related aesthetic traffic between 2023 and 2025 — making it one of the fastest consumer search migrations ever tracked in the aesthetics category.
The Demand Curve Nobody Predicted
That number isn't a rounding error. When Novo Nordisk announced its partnership with Hims & Hers Health in early 2025, GLP-1 access shifted from specialty endocrinology clinics to consumer telehealth — practically overnight. Hims & Hers CEO Andrew Dudum publicly projected GLP-1 prices dropping toward $50/month, a price point that turns semaglutide from a luxury prescription into a mass-market wellness product. The downstream aesthetic consequences landed directly in med spa waiting rooms.
The mechanism is well-documented. Rapid fat loss — particularly in patients losing 15–25% of body weight on GLP-1 agonists — produces facial volume deflation, skin laxity, and accelerated soft-tissue descent. Dr. Arthur Perry, board-certified plastic surgeon and frequent media KOL on GLP-1 aesthetics, has described "Ozempic face" as a predictable sequela of rapid weight loss rather than a drug-specific effect, noting that the deflation pattern often mimics a decade of natural aging compressed into 6–12 months. That's not a niche concern — it's a treatment pipeline.
According to Global Payments Integrated, med spas collectively register 155.8 million visits annually. Even a modest shift in consumer intent — patients arriving post-GLP-1 seeking facial restoration, body contouring, or skin tightening — represents hundreds of thousands of incremental procedure opportunities. The question isn't whether this demand exists. It's whether your practice is positioned to capture it.
How Bundling Practices Are Pulling Ahead on Revenue
Our analysis of 9,371 med spa practices across 339 cities and 36 states shows a clear divergence. Practices that have added structured weight loss programming — whether GLP-1 management, metabolic monitoring, or body composition services — alongside their core aesthetic menu are generating meaningfully higher review volumes and engagement scores than aesthetics-only competitors in the same markets.
The revenue logic is straightforward. A patient on a GLP-1 protocol returns monthly for weight management check-ins. Layer in a quarterly filler or biostimulator session, add a body contouring treatment at the 6-month mark, and that patient's annual value to the practice compounds. Openloop Health's 2026 industry analysis identifies medical weight loss as one of the top service add-ons accelerating the shift from "one-off aesthetic visits" to long-term patient relationships. Practices offering integrated care report patients viewing the med spa as a primary wellness partner — not a discretionary splurge.
The top-performing bundle structures we're observing include GLP-1 management paired with: Sculptra or Radiesse biostimulator series (for facial and body skin tightening), RF microneedling for skin laxity, and non-surgical body contouring (EMSCULPT, CoolSculpting, or ultrasound cavitation) timed to the patient's weight loss plateau. Practices running structured bundles — not ad hoc add-ons — are seeing average transaction values climb 40–65% above their aesthetics-only baseline, based on revenue per visit benchmarks in markets where we have comparative data.
The Clinical Case for Biostimulators Over Volume Fillers
Not all aesthetic responses to GLP-1 deflation are equal. The 2026 Octane Aesthetics Tech Forum surfaced a clear clinical consensus: biostimulators are the preferred first-line response to GLP-1-related facial deflation — not traditional hyaluronic acid volume fillers. The reasoning is structural. Patients who've lost significant facial fat don't just need volume replacement; they need collagen matrix restoration and skin quality improvement to support any volume that's added.
Sculptra (poly-L-lactic acid) and Profhilo (stabilized hyaluronic acid bio-remodeler) are gaining traction specifically in GLP-1 aesthetic protocols because they address the underlying tissue quality problem, not just the visible volume deficit. A 2023 study in Aesthetic Surgery Journal (Fitzgerald et al.) demonstrated that biostimulator-primed tissue showed superior filler longevity and more natural contour outcomes compared to filler-first approaches in volume-depleted patients — a finding that translates directly to the GLP-1 population.
From a practice economics standpoint, biostimulator protocols also have superior patient lifetime value. A Sculptra series typically requires 2–3 sessions spaced 4–6 weeks apart, followed by annual maintenance. That's a built-in return cadence that aligns neatly with a GLP-1 patient's ongoing weight management schedule. Practices that front-load patient education on why biostimulators outperform volume-only approaches in this population are seeing lower drop-off between treatment phases — which directly impacts revenue predictability.
The Pattern: Ratings, Reviews, and Market Visibility
Across the 9,371 practices in our dataset, the average Google rating sits at 4.83, with an average review count of 136. Those numbers sound healthy in isolation — but the spread is extreme. The highest-reviewed practice in our dataset has accumulated 23,598 Google reviews. The lowest has one. That gap in social proof is also a gap in Local Pack visibility, and it's widening as GLP-1 search intent spikes.
When a consumer searches "Ozempic face filler near me" or "GLP-1 weight loss med spa [city]," Google's Local Pack surfaces the three practices with the strongest combination of proximity, relevance, and authority — and review volume is a primary authority signal. Practices that have built review velocity alongside their GLP-1 service rollout are compounding their search advantage. Those that haven't are invisible to the exact patient segment driving 2026's fastest-growing aesthetic demand category.
The AmSpa 2024 Medical Spa State of the Industry Report found that med spas generating over $2M in annual revenue were nearly twice as likely to have active patient review solicitation programs compared to practices under $500K. That's not coincidence — it's infrastructure. The practices winning the GLP-1 bundle opportunity aren't just winning clinically. They're winning the local search battle that determines whether that patient finds them at all.
So What: Three Moves for Practice Owners
The bundle opportunity is real, but capturing it requires intentional positioning — not just adding "GLP-1 support" to a services page and hoping patients connect the dots.
- Build a named protocol, not a loose menu. The practices gaining traction have branded their GLP-1 aesthetic programs — "Renew + Restore," "Body Recomposition Aesthetics," whatever fits their brand voice. A named protocol signals expertise, supports premium pricing, and makes the patient journey legible from the first consult.
- Sequence treatments to the weight loss timeline. GLP-1 patients typically hit their major weight loss plateau at months 4–6. That's the optimal window for body contouring. Facial biostimulator series should begin earlier — ideally at month 2–3, before volume loss accelerates. Practices that time their protocols to the GLP-1 pharmacology see better outcomes and stronger patient retention.
- Match your search presence to patient intent. The consumer searching for GLP-1 aesthetic support is using different language than the Botox patient. "Ozempic skin," "weight loss face treatment," "body contouring after weight loss" — these are high-intent, low-competition keywords in most markets right now. That window won't stay open.
Practice owners: our Competitor Intelligence Reports map your exact Local Pack position against every practice offering GLP-1 or weight loss services in your market — including their review velocity, keyword gaps, and bundle pricing signals. See our intelligence reports to understand where you stand before your competitors do.
— Diana Chen, CEO & Chief Intelligence Officer, AesthetEdge